Scholarlink

<p>Tuberculosis (TB) is a leading cause of morbidity and mortality from a single infectious agent, despite being preventable and curable. Global health initiatives are still hindered by tuberculosis (TB) because of shortcomings in the effectiveness of vaccines, treatment monitoring, and diagnostic instruments available today. Breaking the cycles of Mycobacterium tuberculosis (Mtb) transmission and improving patient outcomes depend on early and accurate detection of active TB. For biomarker-based diagnostics, the World Health Organization has suggested target product profiles. Measurable indicators of biological states, or biomarkers, present encouraging opportunities to fill these gaps. Notwithstanding notable advancements, no single biomarker has yet met all the performance criteria necessary for clinical use. The several functions of biomarkers in tuberculosis are examined in this narrative review, with particular emphasis on their importance in early diagnosis, treatment response monitoring, disease progression prediction, and protective immunity assessment. We review current developments in the molecular, immunological, transcriptomic, proteomic and metabolomic domains, including multi-gene signatures and microRNAs that distinguish latent infection from active tuberculosis. We also further discuss biomarkers are related to immunological modulation, therapeutic targeting, and drug-resistant TB. It is possible to revolutionize TB care and expedite eradication efforts by integrating many biomarker signatures and rigorously validating them across populations and environments.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

The relevance of biomarkers for diagnosis, monitoring treatment response and immunity during tuberculosis infections

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年11月10日

查看全文
  • Prince Amoah Barnie,
  • Festus Agbatey,
  • Godwin Amponsah Asiamah,
  • William Gyamesi,
  • Cynthia A. Adinortey,
  • Foster Kyei

摘要

Tuberculosis (TB) is a leading cause of morbidity and mortality from a single infectious agent, despite being preventable and curable. Global health initiatives are still hindered by tuberculosis (TB) because of shortcomings in the effectiveness of vaccines, treatment monitoring, and diagnostic instruments available today. Breaking the cycles of Mycobacterium tuberculosis (Mtb) transmission and improving patient outcomes depend on early and accurate detection of active TB. For biomarker-based diagnostics, the World Health Organization has suggested target product profiles. Measurable indicators of biological states, or biomarkers, present encouraging opportunities to fill these gaps. Notwithstanding notable advancements, no single biomarker has yet met all the performance criteria necessary for clinical use. The several functions of biomarkers in tuberculosis are examined in this narrative review, with particular emphasis on their importance in early diagnosis, treatment response monitoring, disease progression prediction, and protective immunity assessment. We review current developments in the molecular, immunological, transcriptomic, proteomic and metabolomic domains, including multi-gene signatures and microRNAs that distinguish latent infection from active tuberculosis. We also further discuss biomarkers are related to immunological modulation, therapeutic targeting, and drug-resistant TB. It is possible to revolutionize TB care and expedite eradication efforts by integrating many biomarker signatures and rigorously validating them across populations and environments.